Nkarta to present preclinical data from engineered nk cell platform at the american association for cancer research 2022 annual meeting

South san francisco, calif., march 08, 2022 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a biopharmaceutical company developing engineered natural killer (nk) cell therapies to treat cancer, today announced that it will present four posters at the upcoming american association for cancer research (aacr) annual meeting to be held april 8 to 13, 2022.
NKTX Ratings Summary
NKTX Quant Ranking